

32nd Annual Internal Medicine Review

PRESENTED BY: Jamie Lo, MD, MCR, and Jasper Bash, MD

DATE: April 10th, 2024

Disclosures


No financial disclosures



Objectives

- Review the modern trends of cannabis composition and use
- Define the current recommendations regarding cannabis use in those attempting to conceive
- Discuss the risks of cannabis use relating to sexual function and menopause
- Provide tools and data for counselling patients regarding the potential impacts of paternal or maternal cannabis use and offspring outcomes

Cannabis Legalization



- 40 states and Washington DC have legalized medical cannabis
- 24 states and Washington DC have also legalized recreational (adult use) cannabis


Legal for recreational use Legal for medical use No comprehensive medical program Decriminalized

Cannabis availability




Reference: Oregon Liquor Control Commission, Colorado Department of Revenue, Washington Liquor and Cannabis Board, Alaska Alcohol and Marijuana control office. 2019 Marijuana Business Daily.

Prevalence of Cannabis Use



Cannabis - more than just a weed

- Cannabis sativa plant
- Contains over 600 chemicals
- Delta-9-tetrahydrocannabinol (THC)
 - Main psychoactive component
 - Small and highly lipophilic
 - Rapidly distributed to the brain and fat
 - Metabolized by the liver
 - Half-life is 20-36hrs to 4-6 days
 - Can be detectable up to ~30 days
- THC mechanism of action: Partial binding at C1 (high affinity) and CB2
- CBD mechanism of action: more unknown



Synthetic: Delta-8 & Delta-10 THC

CBD

Cannabidiol

Chemical Formula: C₂₁H₃₀O₂ Molecular Weight: 314.46 g/mol

Date Isolated: 1940
Is it psychoactive: No
Average Dose: 20-40 mg
Concentration in Cannabis: Up

to 20%

Show up on a drug test?: No Anecdotal experiences:
Pain Relief+Relaxation

Delta-8 THC

Δ⁸ Tetrahydrocannabinol

Chemical Formula: C₂₁H₃₀O₂ Molecular Weight: 314.46 g/mol

Date Isolated: 1941
Is it psychoactive: Yes
Average Dose: 20-60 mg
Concentration in Cannabis: < 1%
Show up on a drug test?: Yes
Anecdotal experiences:
Calming +Uplifting

Delta-9 THC Δ° Tetrahydrocannabinol

Chemical Formula: C₂₁H₃₀O₂ Molecular Weight: 314.46 g/mol

Date Isolated: 1964
Is it psychoactive: Yes
Average Dose: 10-30 mg
Concentration in Cannabis: Up
to 30%
Show up on a drug test?: Yes

Anecdotal experiences: Euphoric + Chill

Delta-10 THC

Chemical Formula: C₂₁H₃₀O₂ Molecular Weight: 314.46 g/mol

Date Isolated: 1984
Is it psychoactive: Yes
Average Dose: 20-60 mg
Concentration in Cannabis: < 1%
Show up on a drug test?: Yes
Anecdotal experiences:
Energizing + creativity

Created with Biorender.com

Limitations of the Urine Drug Screen


- Are often immunoassays that detect the major urinary metabolite of THC (11-nor-delta-9-tetrahydrocannabinol-9-carboxylic acid)
- Prone to false positives
 - NSAIDs and PPIs have been reported to cause false positives on drug screens
 - If a false positive or negative is suspected, confirmatory testing is with gas chromatography-mass spectrometry or liquid chromatography-tandem mass spectrometry
- Synthetic or designer cannabinoids are not detected by urine drug screens



Cannabinoid Receptor Expression




- Wide distribution of expression
- Enhanced expression in CNS, PNS and endocrine tissues
- Placenta
- Airway epithelial cells and endothelial cells




Enhanced expression in immune-derived cells Expressed in airway

CB₂


macrophages, eosinophils, mast cells, most WBC



Increasing potency of cannabis



Accuracy of Labeling



Limitations of existing studies

- Recruitment bias
- Retrospective or observational design
- Patient self-report
- Confounded by tobacco, polysubstance use, small sample size, inaccurate dosing information
- Lack of quantification/timing of exposure
- Most studies reflect cannabis exposure through smoking
- Existing literature is largely from the 1980s when cannabis products were less potent



How Much THC are They Getting?


- Colorado Guidelines
 - 5 mg
 - 10 mg
 - 20-30 mg
- Harder to quantify
 - Dabbing (vaporized hash oil)
 - Smoking
 - Vaporizing
- So just ask



Cannabis and male reproductive health



Male
HypothalamusPituitary-Gonadal
(HPG) Axis



Male Infertility Workup

- Semen Analysis (x2)
- Hormones:
 - Follicle stimulating hormone
 - Luteinizing hormone
 - Testosterone
- Testicular Volume
- Sexual Function

Semen Parameter	WHO 2021
Semen volume (mL)	1.4 (1.3–1.5)
Total sperm number (10 ⁶ per ejaculate)	39 (35–40)
Total motility (%)	42 (40–43)
Progressive motility (%)	30 (29–31)
Non progressive motility (%)	1 (1–1)
Immotile sperm (%)	20 (19–20)
Vitality (%)	54 (50–56)
Normal forms (%)	4 (3.9–4)


Worsened semen parameters

- Strongest evidence of an adverse impact of cannabis on male fertility
- Reduction in:
 - Sperm count
 - Concentration
 - Motility
 - Viability
- Abnormal morphology
- Inhibition of capacitation and fertilization



Variable affect on hormones

- Follicle stimulating hormone (FSH)
 - no change
- Luteinizing hormone (LH)
 - Lower
 - Less response to GnRH
- Testosterone
 - Variable
 - Effect may be acute and transient



Sexual Desire is Increased


- Any use: increased coital frequency
 - 8.8 vs 7.8 events/month, p<0.05
- Daily use: 2 or more partners in previous year
 - OR 2.08 for men, 2.58 for women
- Survey in Dispensary
 - Increased orgasmic function
 - Improved erectile function
 - Higher sexual satisfaction




Erectile Function is Compromised

 Erectile dysfunction prevalence is doubled

- Orgasmic function
 - too quickly (OR 2.68)
 - too slowly (OR 2.05)
 - inability to reach (OR 3.94)



Testicular Volume is Decreased




Spontaneous Abortion Increases



- 1,535 North American couples from 2013-2019
- Preconception cannabis use:
 - <1 time/week: 9%
 - ≥ 1 time/week: 8%
- Couples with male partners who used cannabis ≥ 1 time/week preconception had a higher risk of spontaneous abortion
 - HR 2.0 (CI 1.2-3.1)
 - Even with non-using female partner


Possibility for recovery?

- Rhesus macaques (n=6) with THC exposure for ~7 months
- THC discontinued for 4 months
- Partial recovery noted



Take-Home Points


- Cannabis use is increasing among reproductive aged men
- Negative impact on fertility and sexual health, with likely dosedependent and reversible effects
- Men interested in fertility should be counselled towards cessation or decreased use
- Those using cannabis medically should weigh the benefits of use with potential fertility risks and attempt reduced consumption



Impact of Cannabis Co-Use

Nicotine:

- Reduced sperm health
- ED (Nitric oxide perturbation)
- Low libido
- Increased pregnancy loss (dose-dependent)
- Birth defects (dose-dependent)
- Abnormal offspring neurobehavior
- Heritable decreased fertility



Cannabis and female reproductive health



Cannabis and Female Sexual Function


- Overall mixed research findings challenges with objective measurements
- Potential adverse affects:
 - Variability in response (e.g., individual, dose, strain)
 - Dose-dependent (higher vs. lower doses may have inhibiting effects)
 - May inhibit orgasm
- Potential benefits include:
 - Increased orgasm frequency and satisfaction
 - Enhanced arousal, pleasure, and sensory focus
 - Reduced anxiety and inhibitions
 - Relief from urogenital pain



Cannabis Use on Fertility


Prior human studies are limited by:

- Difficulty defining dose/exposure
- Polysubstance Use
- Non-physiologic route of ingestion



Cannabis use decreases probability to conceive

- Prospective cohort study (n=1,228) of women aged 18-40yo with prior pregnancy loss in 2006-2012
- Preconception use was associated with reduced fecundability (OR 0.59; 95% CI 0.38-0.92)
- Preconception use was associated with:
 - Increased frequency of intercourse per cycle
 - Anovulation
 - Decreased live births
- No association with pregnancy loss



Take-Home Points

- For most couples, cannabis use likely will not affect their ability to conceive but for couples with subfertility or infertility, it could be a contributing factor
- Impact the body's natural hormone cycles
- Increase the risk for miscarriage
- Exacerbate existing infertility factors




Preconception cannabis use and impact on offspring

Paternal cannabis use

- Impacted sperm DNA methylome that can persist despite cessation
- Select sperm DNA methylation changes and genes affected are associated with developmental processes
- May influence short- and longer-term offspring health

Maternal cannabis use


- Increased anxiety behavior and perturbation of the brain epigenome in offspring
- Increased offspring addiction vulnerability later in life



Cannabis Use in Pregnancy

- Most commonly used federally illicit drug in pregnancy
- Self-reported use in pregnancy ranges from 2% to 30%
- Potency of cannabis products has increased 3-fold the last 20 years

Prevalence of past-month cannabis use



Perceived Benefits

Survey respondents – WIC mothers	Ever use % (n)	Current use % (n)	Past use % (n)
To help with depression/anxiety/stress	35% (164)	63% (60)	28% (103)
To help with pain	29% (135)	60% (57)	21% (78)
To help with nausea/vomiting	23% (108)	48% (46)	17% (62)
For fun/recreation	59% (277)	39% (37)	65% (240)
Other reason	16% (75)	14% (13)	16% (58)

Where Do Patients Get Their Information?

- Limited health care counseling
- Internet searches
- Parenting blogs, online groups
- Dispensaries



Where Do Our Patients Get Information?

- Statewide cross-sectional study of dispensaries in Colorado (n=400)
- Mystery shopper study, caller was 8 weeks pregnant with nausea
- Nearly 70% had a product recommendation, predominantly edibles
- 65% based recommendations on personal opinion
- 32% recommended discussing with OB provider without prompting

Phone Script Cited Here...

"Hi, I'm 8 weeks pregnant and feeling really nauseated. Are there any products that are recommended for morning sickness?"

Prompts in response to no recommendation:

- 1. What if I have a medical card? (If asked why you have a card, state it is for chronic pain from a car accident.)
- 2. Why not?

Prompts in response to recommendation:

- 1. What product?
- a. Why?
- 2. How often should I use it?
- 3. Is it safe to take during pregnancy?
- a. If only maternal risks are addressed, ask; is it also safe for my baby?
- b. If only fetal risks are addressed, ask: Is it also safe for me?

Before closing call:

Should I talk to my doctor about this (if no recommendation previously made to discuss with health care provider)?

Outcomes of Prenatal Cannabis Exposure

Maternal

- Increased risk of anemia
- Increased cyclic vomiting and/or hyperemesis syndrome
- Increased hypertensive disorders

Fetal/Neonatal

- Fetal growth restriction and lower birth weight
- Preterm birth
- Stillbirth and miscarriage
- Increased NICU admissions
- Altered neurodevelopment



Impact of Prenatal Cannabis Use on Offspring

Prenatal cannabis exposure is associated with an increased risk of:

Infancy

- Decreased ability to self-soothe
- Sleep disturbances

Childhood

- Poorer memory, verbal reasoning skills
- Less attentive, more impulsive and hyperactive
- Symptoms of depression, anxiety

Adolescence

- Continued hyperactivity, impulsivity, inattention
- Reduced school performance




Cannabis and Nicotine-product Co-Use

Co-use of nicotine and cannabis vs. none is associated with a 4-fold increased risk in infant death, and nearly a 2-fold increased risk vs. use of nicotine or cannabis alone

Outcome	Substance used, % of participants				
	Unexposed (n = 3 039 129)	Cannabis-use (n = 23 007)	Nicotine-product use (n = 56 811)	Both (n = 10 312)	
Hypertensive disease ^b	7.6	12.3	9.6	11.2	
Preterm delivery <37 wk	6.6	12.2	12.0	17.5	
Preterm delivery <32 wk	0.8	2.1	1.8	2.9	
SMM	1.3	2.3	2.1	2.6	
Nontransfusion SMM	0.4	0.8	0.7	1.0	
NICU admission	10.0	15.6	17.8	22.5	
Small for gestational age	8.5	14.3	13.7	18.0	
Respiratory distress syndrome	3.4	5.9	5.5	7.5	
Infant death	0.3	0.7	0.7	1.2	
Neonatal death	0.2	0.3	0.3	0.6	
Postneonatal death	0.1	0.4	0.4	0.6	
Hypoglycemia	2.1	3.5	3.0	3.8	
Bronchopulmonary dysplasia	0.1	0.2	0.1	0.2	

Cannabis and Nicotine-product Co-Use



Co-use of nicotine and cannabis

vs. none is associated with a **4-fold** increased risk in infant death, and nearly a **2-fold** increased risk vs. use of nicotine or cannabis alone.

Outcome	Substance used, % of participants				
	Unexposed (n = 3 039 129)	Cannabis-use (n = 23 007)	Nicotine-product use (n = 56 811)	Both (n = 10 312)	
Hypertensive disease ^b	7.6	12.3	9.6	11.2	
Preterm delivery <37 wk	6.6	12.2	12.0	17.5	
Preterm delivery <32 wk	0.8	2.1	1.8	2.9	
SMM	1.3	2.3	2.1	2.6	
Nontransfusion SMM	0.4	0.8	0.7	1.0	
NICU admission	10.0	15.6	17.8	22.5	
Small for gestational age	8.5	14.3	13.7	18.0	
Respiratory distress syndrome	3 4	5 9	5 5	7 5	
Infant death	0.3	0.7	0.7	1.2	
Neonatal death	0.2	0.3	0.3	0.6	
Postneonatal death	0.1	0.4	0.4	0.6	
Hypoglycemia	2.1	3.5	3.0	3.8	
Bronchopulmonary dysplasia	0.1	0.2	0.1	0.2	

Offspring Vulnerability to Drug Addiction

- The endocannabinoid system regulates dynamic changes to reward pathways:
 - Mesolimbic dopamine pathway
 - Reward-associated behaviors
- Cannabis exposure in the prenatal and postnatal period can potentially disrupt normal development and increase vulnerability to drug addiction
- More notable in male offspring
- Dose-dependent effect



Transfer of Cannabis in Breastmilk

- 84% of women who used while pregnant continued while breastfeeding
- About 2.5% of inhaled cannabis is transferred into breastmilk
- 56% of new parents did not know THC is transferred to breast milk
- Only 30% of patients report receiving postnatal counseling on THC in breast milk
- Exposed infants scored poorly on Psychomotor Developmental Index



Cannabis and Menopause – US study

- Perimenopausal (n=131) and post-menopausal (n=127) participants completing surveys on symptomatology and cannabis use
- 86.1% reported current cannabis use with 78.7% for menopause-related symptoms
 - Most common is for sleep disturbance (67.4%) and mood/anxiety (46.1%)
- Perimenopausal participants had an increased use of cannabis to treat menopauserelated mood/anxiety symptoms compared to postmenopausal participants
- Modes of cannabis use:
 - Smoking (84.3%)
 - Edibles (78.3%)



Cannabis and Menopause - Canada study

- 1,485 participants surveyed median age 49yo
 - Perimenopausal (33%), postmenopausal (35%)
- 499 (34%) reported current cannabis use and 978 (66%) indicated ever using cannabis
- Most common reasons for cannabis use were sleep (65%), anxiety (45%) and muscle/joint achiness (33%)
- 74% of current users reported it was helpful for symptoms



Harm Reduction Approaches

"Harm reduction is the idea that since we cannot completely eliminate risk and harm, we should do our best to minimize them."

National Harm Reduction Coalition & Academy of Perinatal Harm Reduction

- Consider substituting form of cannabis used
- Avoid synthetic cannabis or cannabis concentrates
- If inhalation, use a vaporizer to avoid risk of exposure to pyrolytic compounds
- Do not mix cannabis with tobacco
- Do not use a cigarette filter when using

Provider Resources

- SAMHSA Substance Use and Mental Health Services Administration
- STEM (Systematically Testing the Evidence on Marijuana www.cannabisevidence.org
- Colorado Cannabis www.cannabis.Colorado.gov
- Canada Cannabis -<u>www.canada.ca/en/services/health/campaigns/cannabis/health-effects.html</u>
- American Society of Reproductive Medicine https://www.asrm.org/topics/topics-index/alcohol-and-drug-use/



References

- The National Survey on Drug Use and Health 2019, Substance Abuse and Mental Health Serices Administration
- Gundersen, T. D. et al. Association between use of marijuana and male reproductive hormones and semen quality: a study among 1,215 healthy young men. Am. J. Epidemiol. 182, 473-481 (2015).

Thistle, J. E. et al. Marijuana use and serum testosterone concentrations among U.S. males. Andrology 5, 732–738 (2017). Gundersen TD, Jørgensen N, Andersson AM, Bang AK, Nordkap L, Skakkebæk NE, Priskorn L, Juul A, Jensen TK. Association Between Use of Marijuana and Male Reproductive Hormones and Semen Quality: A Study Among 1,215 Healthy Young Men. Am J Epidemiol. 2015 Sep

15;182(6):473-81. doi: 10.1093/aje/kwv135. Epub 2015 Aug 16. PMID: 26283092.

• Feiby L Nassan, Mariel Arvizu, Lidia Mínguez-Alarcón, Paige L Williams, Jill Attaman, John Petrozza, Russ Hauser, Jorge Chavarro, Marijuana smoking and markers of testicular function among men from a fertility centre, Human Reproduction, Volume 34, Issue 4, April 2019, Pages 715–723,

- Wise LA, Wesselink AK, Hatch EE, Rothman KJ, Mikkelsen EM, Sørensen HT, Mahalingajah S. Marijuana use and fecundability in a North American preconception cohort study. J Epidemiol Community Health. 2018 Mar;72(3):208-215. doi: 10.1136/iech-2017-209755. Epub 2017 Dec 22. PMID: 29273628.
- J. C. Hedges, C. B. Hanna, J. C. Bash, E. R. Boniface, F. C. Burch, S. Mahalingaiah, V. H. J. Roberts, J. J. D. Terrobias, E. C. Mishler, J. V. Jensen, C. A. t. Easley, J. O. Lo, Chronic exposure to delta-9-tetrahydrocannabinol impacts testicular volume and male reproductive health in rhesus macaques. Fertil Steril 117, 698-707 (2022).
- Smith AMA, Ferris JA, Simpson JM, et al. Cannabis use and sexual health. J Sex Med 2010; 7(2 Pt 1):787 793.
- Sun AJ, Eisenberg ML. Association between marijuana use and sexual frequency in the United States: a population-based study. J Sex Med 2017; 14:1342 – 1347.
- Bhambhvani HP, Kasman AM, Wilson-King G, Eisenberg ML. A survey exploring the relationship between marijuana use characteristics and sexual function in men. Sex Med 2020: 8:436 – 445.
- Elbendary MA, El-Gamal OM, Salem KA. Analysis of risk factors for organic erectile dysfunction in Egyptian patients under the age of 40 years. J Androl 2009; 30:520 - 524.
- Pizzol D, Demurtas J, Stubbs B, et al. Relationship between marijuana use and erectile dysfunction: a systematic review and meta-analysis. Am J Mens Health 2019: 13:1557988319892464.
- Cannabis Clinicíans Colorado. Medical marijuana new patient success guide. Available from: http://coscc.org/wp-content/uploads/2016/07/CCC-General-CannabisAsMedicine-2017DRAFT.pdf Last accessed March 1, 2025.
- du Fossé, N. A. et al. Paternal smoking is associated with an increased risk of pregnancy loss in a dose-dependent manner: a systematic review and meta-analysis. FS Rev. 2, 227–238 (2021).
- Zhou, Q. et al. Association between preconception paternal smoking and birth defects in offspring: evidence from the database of the National Free Preconception Health Examination Project in China. BJOG 127, 1358-1364 (2020).
- Hawkey, A. B. et al. Paternal nicotine exposure in rats produces long-lasting neurobehavioral effects in the offspring. Neurotoxicol Teratol. 74, 106808 (2019)
- Sharma, R., Harley, A., Agarwal, A. & Esteves, S. C. Cigarette smoking and semen quality: a new meta-analysis examining the effect of the 2010 World Health Organization Laboratory Methods for the Examination of Human Semen. Eur. Urol. 70, 635-645 (2016).
- Kovac, J. R., Labbate, C., Ramasamy, R., Tang, D. & Lipshultz, L. I. Effects of cigarette smoking on erectile dysfunction. Andrologia 47, 1087–1092 (2015).